HIM
BCRX icon

Hillsdale Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hillsdale Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-639,100
Closed -$6.08M – 661
2026
Q1 		$6.08M Buy
639,100
+80,000
+14% +$621K 0.17% 145
2025
Q4 		$4.36M Sell
559,100
-2,500
-0.4% -$18.1K 0.12% 232
2025
Q3 		$4.26M Buy
561,600
+25,600
+5% +$213K 0.13% 230
2025
Q2 		$4.8M Buy
536,000
+13,700
+3% +$128K 0.18% 176
2025
Q1 		$3.92M Sell
522,300
-19,800
-4% -$160K 0.2% 117
2024
Q4 		$4.08M Buy
542,100
+541,270
+65,213% +$4.11M 0.21% 129
2024
Q3 		$6.31K Buy
+830
New +$6.31K ﹤0.01% 561
2020
Q3 		– Sell
-172,000
Closed -$820K – 579
2020
Q2 		$820K Buy
+172,000
New +$687K 0.07% 206

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Hillsdale Investment Management's BCRX Position: Q2 2026 in Review

Hillsdale Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 639,100 shares — an estimated $6.08M sold.

Hillsdale Investment Management first reported a position in BCRX in Q2 2020 and held it in 8 quarters. The position peaked at $6.08M in Q1 2026. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Hillsdale Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 639,100 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.08M.
  • Hillsdale Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • Hillsdale Investment Management's BioCryst Pharmaceuticals position peaked at $6.08M in Q1 2026.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.